Atrium Therapeutics, Inc. Overview
RNA market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
RNA price chart · 1M
- O
- 8.45
- H
- 8.57
- L
- 8.30
- C
- 8.30
- Vol
- 4,503.00
Daily history from Jun 12, 2020
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $8.45
- Previous Close
- $8.70
- Day High
- $8.57
- Day Low
- $8.30
- 52 Week High
- $73.05
- 52 Week Low
- $7.53
- 7 Day Return
- +0.61%
- 30 Day Return
- +3.88%
- 90 Day Return
- -32.74%
- 1 Year Return
- -88.11%
- Daily Notional Volume
- $37.4K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.89 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.20 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -209.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.49 – $73.06 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $193.4M · P/B 0.76 · P/S 4.69.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured